Online inquiry

IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ298MR)

This product GTTS-WQ298MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD37 gene. The antibody can be applied in research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Mus musculus
RefSeq NM_001040031.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 951
UniProt ID P11049
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ298MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12848MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ONC-005
GTTS-WQ5784MR IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA cetuximab-IR700
GTTS-WQ11153MR IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MDX-1333
GTTS-WQ15705MR IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA VEGF Trap
GTTS-WQ4032MR IVTScrip™ mRNA-Anti-IL23A, BI 655066(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BI 655066
GTTS-WQ6284MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CS-1001
GTTS-WQ5333MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CD20-TCB (2:1)
GTTS-WQ12738MR IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA OMP-313M32
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW